$2.56
2.29%
Nasdaq, Oct 01, 04:00 pm EDT. Closed.
ISIN
US65487U1088
Symbol
NKTX

Nkarta Inc Stock price

$2.56
-0.14 5.19% 1M
+0.37 16.90% 6M
+0.71 38.38% YTD
+0.43 20.19% 1Y
+1.25 95.42% 3Y
-24.32 90.48% 5Y
-45.34 94.66% 10Y
-45.34 94.66% 20Y
Nasdaq, Closing price Thu, Oct 01 2026
-0.06 2.29%
ISIN
US65487U1088
Symbol
NKTX
Industry

Is Nkarta Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$183.4m
Enterprise Value
$600.0k
Net debt
positive
Cash
$182.8m
Shares outstanding
71.6m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
0.7
Financial Health
Equity Ratio
77.3%
Return on Equity
-
ROCE
-39.8%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$7.4m | -
SBC as % of FCF
-
SBC Growth 1Y
-42.1%
Share Count Growth 1Y
0.8%
Shareholder Yield
-0.8%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-115.3m
EBIT
$-125.0m
Net Income
$-117.3m
Free Cash Flow | ex SBC
$-93.9m | $-101.3m
Growth
Revenue | estimate
- | -
EBITDA
3.3%
EBIT
2.7%
Net Income
-7.4%
Free Cash Flow
6.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.6
FCF per Share
$-1.3
Short interest
6.1%
Employees
108
Rev per Employee
-

Nkarta Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Nkarta Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Nkarta Inc forecast:

Buy
92%
Hold
8%

Financial data from Nkarta Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
28% 28%
-
- Research and Development Expense 100 100
7% 7%
-
-115 -115
3% 3%
-
- Depreciation and Amortization 9.64 9.64
4% 4%
-
EBIT (Operating Income) EBIT -125 -125
3% 3%
-
Net Profit -117 -117
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nkarta Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nkarta Inc Stock News

Neutral
GlobeNewsWire
●
2 months ago
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve as Chair of the Audit Committee. The company has also str...
Neutral
GlobeNewsWire
●
5 months ago
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026 Cash balance of $266.7 million on March 31, 2...
Neutral
GlobeNewsWire
●
6 months ago
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol a...
More Nkarta Inc News

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Mr. Hastings
Employees 108
Founded 2005
Website www.nkartatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today